The collaboration follows the approval of QDENGA's marketing authorization by India's Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India's first approved dengue vaccine, the approval marks an important milestone in the country's efforts to strengthen dengue prevention and management.
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.